Neuroprotection in Glaucoma: From Memantine's Failure to Nicotinamide's Promise
核心洞察
Glaucoma (搜索) is a progressive neurodegenerative disease where retinal ganglion cell loss continues despite adequate intraocular pressure control, driving the search for IOP-independent neuroprotective therapies.
The landmark Phase III memantine trials, enrolling 2,298 patients at a cost exceeding $80–100 million, failed to demonstrate significant benefit on visual field progression, reshaping future trial design.
Nicotinamide (vitamin B3) has emerged as a leading neuroprotective candidate, with preclinical studies showing up to 93% prevention of glaucoma (搜索) in mouse models and early clinical trials demonstrating improved inner retinal function.
The pursuit of neuroprotective therapies for glaucoma (搜索)—treatments that shield retinal ganglion cells (RGCs) from degeneration independent of intraocular pressure (IOP)—has reached a critical inflection point. Nearly two decades after the field's most ambitious clinical program ended in disappointment, a new generation of candidates, refined trial designs, and innovative biomarkers are renewing hope that IOP-independent neuroprotection may finally become a clinical reality.
Glaucoma (搜索), a progressive neurodegenerative disease and leading cause of irreversible blindness worldwide, is characterized by the gradual loss of RGCs and their axons. While IOP reduction remains the only evidence-based treatment, disease progression commonly occurs despite adequate pressure control. This recognition has spurred intense investigation into mechanisms beyond IOP—including excitotoxicity, mitochondrial dysfunction, oxidative stress, neuroinflammation, and neurotrophic factor deprivation—that contribute to RGC death.
The Memantine Experience: Lessons from a Landmark Failure
The memantine glaucoma (搜索) program stands as the most extensive neuroprotection trial effort in ophthalmology history. Two identically designed, randomized, double-masked, placebo-controlled, multicenter Phase III trials enrolled 2,298 patients with bilateral open-angle glaucoma over 48 months. Patients received memantine 20 mg, memantine 10 mg, or placebo daily.
The results were unequivocally negative. Neither memantine dose significantly delayed glaucomatous progression in individual studies or pooled analyses. In an unexpected finding, standard automated perimetry (SAP) analysis in the first study showed a statistically higher cumulative probability of visual field progression with memantine versus placebo at month 48. The trials, which cost an estimated $80–100 million and spanned nearly five years, generated critical lessons for the field.
Identified limitations included enrollment of patients with relatively advanced disease (mean cup-to-disc ratio approximately 0.8), potential insensitivity of functional endpoints for detecting neuroprotection over feasible durations, and variable IOP management across sites. As Weinreb and colleagues noted, the protocol required subjects to stop study treatment once progression was declared, limiting the ability to detect post-treatment benefit.
Nicotinamide: The Leading Contender
Nicotinamide (vitamin B3) has emerged as arguably the most compelling neuroprotective candidate based on the depth and reproducibility of preclinical evidence. The foundational work by Williams et al, published in Science, demonstrated that age-related declines in retinal NAD render RGC mitochondria vulnerable to IOP-dependent stresses. Using the DBA/2J mouse model of hereditary glaucoma (搜索), oral nicotinamide supplementation at 2,000 mg/kg/day resulted in 93% of eyes not developing glaucoma—approximately a 10-fold reduction in risk. Critically, nicotinamide did not alter IOP, confirming an IOP-independent mechanism.
A companion study showed that combining nicotinamide with the Wallerian degeneration slow allele (WldS) produced additive protection, with 94% of eyes absent of glaucomatous neurodegeneration. More recently, Cimaglia et al demonstrated in 2024 that a nicotinamide-enriched diet provides robust dendritic protection in a rat model of experimental glaucoma (搜索).
Clinical translation has been rapid. Hui et al conducted a randomized, double-masked, placebo-controlled crossover trial in 49 glaucoma (搜索) patients receiving nicotinamide at 1.5 g/day escalating to 3.0 g/day. After 12 weeks, there was a significant improvement in the photopic negative response (PhNR) Vmax, a direct electrophysiological marker of inner retinal function, compared to placebo. A Phase II trial by De Moraes et al further demonstrated that combined nicotinamide and pyruvate safely enhanced short-term visual function in open-angle glaucoma patients.
Multiple Phase III trials are now testing NAD augmentation, including the TGNT, TAMING, and NAMinG studies across Australia, Singapore, Sweden, and the UK. Nicotinamide riboside, an alternative NAD precursor, is also under investigation in a 125-patient, 24-month randomized trial using retinal nerve fiber layer thinning as the primary structural outcome.
Brimonidine and the LoGTS Controversy
The Low-Pressure Glaucoma (搜索) Treatment Study (LoGTS) compared brimonidine 0.2% monotherapy versus timolol 0.5% in patients with normal-tension glaucoma over approximately 30 months. Despite similar IOP lowering, visual field progression was observed in only 9% of brimonidine-treated patients who tolerated treatment compared to 39% of timolol-treated patients—a striking fourfold difference.
However, the study suffered from a high differential dropout rate, with substantially more brimonidine patients discontinuing due to local adverse effects including allergic conjunctivitis. Additionally, the timolol arm showed worse progression rates than control groups in other contemporaneous trials, raising the possibility that the difference reflects timolol-associated worsening rather than brimonidine neuroprotection per se.
Citicoline: Mixed Evidence Across Multiple Routes
Citicoline, an endogenous mononucleotide supporting neuronal membrane phospholipid synthesis, has been evaluated through intramuscular, oral, and topical routes. Studies have reported improved visual field performance, enhanced pattern electroretinogram (PERG) and visual evoked potential responses, and improved vision-related quality of life. However, a 2023 systematic review analyzing 10 studies encompassing 424 patients found no significant effects on IOP, visual field mean deviation, RNFL thickness, or PERG amplitude at the group level, highlighting substantial heterogeneity as a major limitation.
Emerging Clinical Candidates
Several novel agents are advancing through clinical development. ONL1204, a first-in-class inhibitor of Fas receptor-mediated apoptosis, has completed a Phase 1b multicenter, randomized, single-masked, sham-controlled study in 25 patients with progressing open-angle glaucoma (搜索). The NT-501 encapsulated cell therapy device, which provides sustained intravitreal CNTF (搜索) secretion, is being evaluated in a randomized, sham-controlled Phase II trial.
Metformin, widely used for type 2 diabetes, is being tested in a Phase II trial based on epidemiological data showing that diabetic patients taking more than 1,500 mg/day had a 25% reduced risk of developing open-angle glaucoma (搜索). Semaglutide, a GLP-1 receptor agonist, is under investigation in the ABSALON Phase III trial, which uses PhNR change as the primary outcome.
Reimagining Trial Design
The failure of standard automated perimetry to detect neuroprotective effects has spurred innovation in endpoint selection. The photopic negative response (PhNR) has been adopted as a primary endpoint in multiple ongoing trials because it provides a direct measure of inner retinal function. A particularly transformative development is AI-guided endpoint selection: a graph attention neural network that uses baseline SAP data to predict the five visual field locations most likely to deteriorate achieved AUCs of 0.883–0.937 for discriminating progressors from non-progressors and could reduce required trial sample sizes by approximately 42%.
Novel biomarkers are also emerging. Neurofilament light chain in aqueous humor has been shown to be significantly elevated in glaucoma (搜索) patients (mean 429 pg/mL vs. 3.1 pg/mL in controls) and may reflect ongoing neurodegeneration rather than historical damage. DARC (Detection of Apoptosing Retinal Cells) enables direct in vivo visualization of individual apoptotic retinal cells, representing the only clinical-stage tool for imaging active apoptotic processes in the retina.
The Path Forward
With multiple well-designed randomized controlled trials of nicotinamide, metformin, semaglutide, ONL1204, and CNTF (搜索) now underway, the next five years may prove decisive. The convergence of AI-guided endpoint innovation, novel biomarkers capable of detecting active neurodegeneration in real time, multi-target combination strategies, and advanced drug delivery systems creates a realistic pathway toward clinically validated neuroprotective therapies. As the field has absorbed the lessons of the memantine failure—regarding endpoint sensitivity, patient selection, and preclinical model relevance—a new generation of better-designed trials may finally deliver on the long-sought promise of IOP-independent neuroprotection in glaucoma (搜索).